Insights Into Metabolic Mechanisms and Their Application in the Treatment of NASH
Phillip J. White, Manal F. Abdelmalek – 4 February 2021
The Role of Life Style Modifications in Comprehensive Non‐Alcoholic Fatty Liver Disease Treatment
Kathleen Viveiros – 4 February 2021
Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial
Samer Gawrieh, Laura A. Wilson, Katherine P. Yates, Oscar W. Cummings, Eduardo Vilar‐Gomez, Veeral Ajmera, Kris V. Kowdley, William M. Rosenberg, James Tonascia, Naga Chalasani – 4 February 2021 – Enhanced liver fibrosis score (ELF) and one of its components, amino‐terminal propeptide of type III procollagen (PIIINP) are promising noninvasive biomarkers of liver histology in patients with nonalcoholic steatohepatitis (NASH).
The Influence of the Microbiome on NAFLD and NASH
Somaya A.M. Albhaisi, Jasmohan S. Bajaj – 4 February 2021
Molecular Mechanisms Linking Nonalcoholic Steatohepatitis to Cancer
Kara Wegermann, Jeongeun Hyun, Anna Mae Diehl – 4 February 2021
Nonalcoholic Steatohepatitis, Sarcopenia, and Liver Transplantation
Rahima A. Bhanji, Yedidya Saiman, Kymberly D. Watt – 4 February 2021
Development and Validation of a Model to Predict Long‐Term Survival After Liver Transplantation
David Goldberg, Alejandro Mantero, Craig Newcomb, Cindy Delgado, Kimberly Forde, David Kaplan, Binu John, Nadine Nuchovich, Barbara Dominguez, Ezekiel Emanuel, Peter P. Reese – 3 February 2021 – Patients are prioritized for liver transplantation (LT) under an “urgency‐based” system using the Model for End‐Stage Liver Disease score. This system focuses solely on waitlist mortality, without considerations of posttransplant morbidity, mortality, and health care use. We sought to develop and internally validate a continuous posttransplant risk score during 5‐year and 10‐year time horizons.
Discovery and Opportunities With Integrative Analytics Using Multiple‐Omics Data
Arjun P. Athreya, Konstantinos N. Lazaridis – 3 February 2021
Living Donor Liver Transplantation for Patients With Hepatocellular Carcinoma: What Are the Optimal Criteria?
Meng Sha, Ying Tong, Qiang Xia – 3 February 2021
Sleep Disturbance Is Associated With the Presence of Portosystemic Collaterals in Patients With Compensated Cirrhosis
Maya Balakrishnan, Caroline Falker, Samantha Conley, Maria Ciarleglio, Yanhong Deng, Nancy S. Redeker, Guadalupe Garcia‐Tsao – 2 February 2021 – Disturbed sleep is common among patients with cirrhosis. The extent to which this is associated with the different stages of compensated cirrhosis is unknown. This study examines whether the presence of portosystemic collaterals, an indicator of clinically significant portal hypertension, is associated with sleep disturbance in compensated cirrhosis.